S2 Ep36: Medical Crossfire: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

PER Podcast Sessions

Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

2M ago 35:33

MP3•Episode home

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Mohamad Mohty, MD, PhD and Surbhi Sidana, MD discuss recent advances in treating and managing newly diagnosed multiple myeloma (NDMM).
Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Analyze efficacy and safety data from recent clinical trials evaluating quadruplet therapy in patients with newly diagnosed multiple myeloma (NDMM)

Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Sanofi.
Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit

1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 8342
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.

You may immediately download your certificate.
Faculty:

Mohamad Mohty, MD, PhD
Professor of Hematology
Head of the Hematology and Cellular Therapy Department, Saint-Antoine
Hospital
Sorbonne University
Paris, France
Disclosures: Consulting Fees: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Novartis, Pfizer, Sanofi, Stemline, Takeda; Grants and contracts from an entity: Janssen, Novartis, Sanofi; Manuscript writing or educational events: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Payment or honoraria for lectures: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Presentations: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Speakers’ Bureau: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda.
Surbhi Sidana, MD
Associate Professor of Medicine
Director, Myeloma Disease Focused Group
Division of BMT & Cell Therapy
Stanford University
Stanford, CA
Disclosures: Consulting or Advisory role: AbbVie, Arcellx, Bioline, Bristol Myers Squibb, Genentech, Janssen, Kite, Legend, Pfizer, Regeneron, Roche, Sanofi, Takeda; Research funding: Allogene Therapeutics, Bristol Myers Squibb, Janssen, Magenta Therapeutics, Novartis.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an artificial intelligence tool.
To learn more about this topic—including information on using minimal residual disease assessment to guide the choice and duration of maintenance therapy, balancing disease- and patient-specific factors to formulate individualized treatment plans, and implementing proactive measures to mitigate treatment-related adverse events in patients with NDMM—go to https://www.gotoper.com/aom-25-ndmm-full-archive-activity

Release Date

July 30, 2025
Expiration Date

July 30, 2026
Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

60 episodes

#Science #Biology #Podcasting Education #Medicine #Spectives